5-HT2B Receptors

Gene structure, expression, and 5-HT2B receptor signaling.-Serotonin function during embryonic development: the 5-HT2B receptor contribution.-  Stem cells to decipher the physiological roles of 5-HT2B receptor signaling.-The serotonergic system in hematopoiesis and hematopoietic disorders.- The 5-HT2B receptor, the immune system and neuroinflammation.-5-HT2B Receptor on Macrophages: What for?.-Bone and 2B Serotonin receptor.-Roles of 5-HT2B receptor in pain.- 5-HT2B receptor, the heart and blood vessels.-5-HT2B receptor in Cardiopulmonary Disease.- Serotonin and cardiac Valves Degeneration in dog.- The discovery of 5-HT2B receptor pharmacology through the understanding of drug-    induced valvulopathy.- Serotonin and fibrosis.- 5-HT2B receptors in liver.- Metabolic Regulation: Insulin secretion and action.- Drugs of abuse affecting 5-HT2B receptors.-The Role of 5-HT2B receptor on Aggression and Drugs of Abuse.- Role of the serotonin 2B receptor in the reinforcingeffects of psychostimulants.- Serotonin 2B receptor interactions with dopamine network: implications for therapeutics in schizophrenia.- A Role for the 5-HT2B receptor in the Neurobiology of Schizophrenia.- 5-HT2B receptors and antidepressants.- Serotonin and the 5-HT2B receptor in amyotrophic lateral sclerosis.

Laurent Monassier is Professor of Pharmacology at the Strasbourg's University, Strasbourg, France, where he leads the Laboratory of NeuroCardiovascular Pharmacology and Toxicology (UR 7296). His research group is interested in the pharmacological modulation of the autonomic nervous system in cardiovascular diseases. In particular, he is interested in developing 5-HT2 receptor antagonists to protect cardiac valves lesions and other 5-HT ligands in various diseases affecting the lung, the heart and the central nervous system. He is also developing new compounds dedicated to various metabolic disorders associated with the metabolic syndrome.

 

 

Luc Maroteaux is Research Director at INSERM U1270, Institut du Fer à Moulin, Sorbonne University, Paris, France, and is leading the "Serotonin, microglia, plasticity and pathologies" team. His research is focusing into the control of neuronal plasticity in the central nervous system and its pathological and pharmacological alterations. In particular, the team discovered that the serotonin 5-HT2B receptor acts in the brain by increasing extracellular serotonin concentrations by a neuron control mechanism that produces serotonin, and that this receptor is involved in impulsive and depressive behaviors. They are currently working on an original concept focusing on the inflammatory origin of certain psychiatric illnesses, always focusing on serotonin.